Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study
American Journal of Nephrology · 2024
DOI: 10.1159/000541493 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Nephrology, 2024. Verfasst von Takayuki Hamano und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Renal Dialysis, Hyperparathyroidism, Secondary, Calcimimetic Agents, Kidney Failure, Chronic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Upacicalcet is a novel injectable calcimimetic. This phase 3 multicenter open-label study aimed to assess the long-term efficacy and safety of upacicalcet in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT).
Methods
Japanese HD patients with serum intact parathyroid hormone (iPTH) levels >240 pg/mL and corrected calcium (cCa) levels ≥8.4 mg/dL were enrolled. Upacicalcet with a dose range of 25–300 µg was administered after each dialysis for 52 weeks. The main efficacy endpoint was the percentage of patients achieving the target iPTH level (60–240 pg/mL).
Results
A total of 157 patients were enrolled, of whom 138 completed the study. Overall, 94.2% of patients achieved the target serum iPTH level at week 52. Neither symptomatic hypocalcemia nor cCa level
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.
- Department of Nephrology, The University of Osaka Graduate School of Medicine, Suita, Japan.
- Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
- Division of Nephrology, Endocrinology, and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Shibuya, Japan.
- Clinical Development Department, Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Japan.
Zitieren
APA
Hamano, T., Koiwa, F., Isaka, Y., Yokoyama, K., Fukagawa, M., Inagaki, Y., Watanabe, Y. S., Honda, D., & Akizawa, T. (2024). Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study. American Journal of Nephrology. https://doi.org/10.1159/000541493
Vancouver
Hamano T, Koiwa F, Isaka Y, Yokoyama K, Fukagawa M, Inagaki Y, et al. Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study. American Journal of Nephrology. 2024. doi:10.1159/000541493
BibTeX
@article{Hamano2024,
author = {Hamano, Takayuki and Koiwa, Fumihiko and Isaka, Yoshitaka and Yokoyama, Keitaro and Fukagawa, Masafumi and Inagaki, Yosuke and Watanabe, Yukihisa S and Honda, Daisuke and Akizawa, Tadao},
title = {Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study},
journal = {American Journal of Nephrology},
year = {2024},
doi = {10.1159/000541493}
}
EUVIMED